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Bilateral regulatory action of corticotropin-releasing hor-
mone on immune-mediated inflammation
YANG Ce 杨策 and JIANG Jian-xin 蒋建新*
Corticotropin-releasing hormone (CRH), the keyregulatory factor in posttraumatic stress, playsa bilateral role via activation of global stress
response and peripheral immunoregulatory response.
Hypothalamus-pi tui tary-adrenal  (HPA) and
sympathetico-adrenomedullary (SAM) axes are the
most important for the CRH mediated neuroendocrine
responses in trauma. The stress-induced release of
hypothalamic CRH leads to systemic secretion of
glucocorticoid, epinephrine and norepinephrine, involved
in the regulation of immune inflammatory process.
Otherwise, the cytokines from immune cells could ini-
tiate the CRH secretion through various routes. The
extensive distribution of CRH and its receptors in the
centrum and periphery indicates the comprehensive
effects in the neuroendocrine immunoregulatory
network. There is growing evidence that the CRH medi-
ated neuroendocrine responses have reasonable im-
munosuppressive or immunoenhancing actions depend-
ing on their concentration, timing and immune
parameters.1-2 This review summarized the regulatory
role of CRH in immune inflammatory responses in view
of the neuroendocrine immune network. Present evi-
dences demonstrate that CRH links neuroendocrine and
immune system, forming a cohesive and integrated early
host defense system to trauma and injury, which is of
great importance for the controlling of uncontrolled in-
flammatory responses.
Structure and gene locus of CRH
CRH is initially discovered from the hypothalamus
extracts by Saffran and Schally. Vale et al separated
the 41 peptide CRH and identified its amino acid se-
quence in ovine hypothalamus. The successive re-
searches confirmed that different species, such as rat,
mice, humans, have similar CRH molecular structure.
The mouse CRH gene is located on chromosome 3, a
region syntenic with the human CRH locus 8q12-13,
including two exons, separated by an intron in its 5-
untranslated region, similar to that in rats and sheep.
The human CRH promoter comprises a cAMP response
element. Its intron has restriction element-1/ neuron
restriction silencing element (RE-1/NRSE) sequence.
Alignment of the CRH sequence of human, rats and
sheep have revealed the highest degree of homology in
In trauma, infection and hemorrhagic shock derived
stress, primary and secondary injury may result in severe
derangement in the internal environment. The abnormal
changes of immune-mediated inflammation interfere its
pathogenesis and development directly. In recent years,
various aspects of neuroendocrine responses, especially
the regulatory effects of hypothalamic-pituitary-adrenal and
sympathetico-adrenomedullary axes in inflammatory dis-
eases have been the focus of research. Most importantly,
corticotropin-releasing hormone (CRH) acts as a key player
in the regulation of interactions between neuroendocrine
and immunity both directly and indirectly. The paper sum-
marized the recent development of CRH in the immune-me-
diated inflammation.
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the 330 base pair (bp) long proximal segment of the 5'-
flanking region, suggesting that it may play a very im-
portant role in CRH gene regulation for survival. The
regulatory elements of human CRH gene include
CAMP-responsive enhancer, CREB enhancer se-
quence/PKA activation phorbol ester, Phorbol ester, 12-
O-tetradecanoyl phorbol-13-acetate (TPA)-response
element (TRE) or AP-1 site/PKC activation, glucocorti-
coid response element (GRE), estrogen response ele-
ment (GRE), TATA box, etc.3 The newly discovered CRH
related peptide family, urocortins, is also involved in
the integration of various stress responses. CRH and
urocortins have function via G-protein coupled receptors,
CRHR1 and CRHR2 with different affinity.
Expression and distribution of CRH
CRH is extensively distributed in central nervous
system (CNS) and peripheral sites including immune
tissues and inflammatory sites. The hypothalamus is
the main origin of CNS CRH. CRH is located in the
small cells in paraventricular nucleus (PVN) and other
nucleus, with coexistence of many other neuropeptides,
such as arginine vasopressin, oxytocin, dynorphin,
neurotensin. Other neurons releasing CRH are mainly
in the neocortex, limbic system, brain stem related to
the regulation of automatic nervous system, and inter-
mediate lobe, with the highest expression in amygdale,
bed nucleus of the stria terminalis, central gray, dorsal
tegmental nucleus, nucleus ceruleus and parabrachial
nuclei. The cytokines, TNF-α, IL-1 and IL-6 released
in immune cells could immediately stimulate the CRH
secretion in hypothalamus.4, 5 Meanwhile, peripheral
CRH and designated immunoreactive CRH are distrib-
uted in circulating leukocytes, thymocytes, splenic
cells, adrenal cortex and medulla, Leydig cells, gut de-
rived epithelial cells, nerve fiber, some endocrine cells,
skin, lungs, testis, placenta, etc. The normal CRH level
in plasma is only 6.2 ng/L, while it is elevated in
inflammation. In the early phase of inflammatory
responses, the immuoreactivity of CRH in dorsal root
ganglion, posterior horn, sympathetoblast and sympa-
thetic ganglion indicates that the peripheral CRH is
mainly located in peripheral nerve. The immune stimu-
lus with LPS, ConA, PHA or 12-O-tetradecanoylphorbol-
13-acetate could all enhance the secretion of CRH in
lymphocytes. The CRH in skin displays differential
expression, depending on cell type, physiological or
pathological status.
Glucocorticoid plays a key role in the synthesis and
releasing of CRH.6 The expression of CRH mRNA and
peptide is downregulated with glucocorticoid treatment.
The AtT-20 cells stably transfect human CRH gene, which
can also be negatively regulated. The expression of CRH
mRNA is inhibited in PVN of the dexamethasone-
treated adrenalectomized rats. Otherwise, CRH gene
expression is also regulated in human placenta and
amygdale central nucleus with glucocorticoid
administration.
Central CRH in the crossroad of neuroendocrine
axes
The posttraumatic stress can initiate the CRH se-
cretion in hypothalamus, followed by the release of
adrenocorticotropic hormone (ACTH) in pituitary gland
and adrenal hormones. Glucocorticoid may inhibit the
ACTH release and even the CRH secretion. ACTH can
also limit the CRH secretion of hypothalamus.
Meanwhile, CRH can work in a glucocorticoid indepen-
dent manner, which is related to the central stimulation
of the efferent activities of adrenergic nerve. The im-
mune system could be coincidently involved in the re-
lease of these hormones and in turn responses.
The stimulation of CRH is the principal route in im-
mune activation of HPA axis.7 The CRH deficiency can
reduce the secretion of glucocorticoid and enhance the
inflammation in respiratory tract and lung dysfunction.8
The intracerebroventricular administration of CRH can
inhibit the LPS-induced margination, adherence,
emigration, chemotaxis and the expression of adher-
ence factor ICAM-1. But the exogenous glucocorticoid
supplement fails to reach the down-regulatory effect in-
duced by CRH, indicating the existence of the gluco-
corticoid independent mechanism. The research has
showed that the levels of serum ACTH and corticoster-
one both increase in adult CRH knockout (KO) mice
and their wild-type (WT) littermates after intraperitoneal
injection of LPS, although the level is blunted to some
extent in CRH KO mice. The results indicate that the
cytokines released after LPS stimulation could act on
pituitary and adrenal gland directly to compensate the
CRH deficiency and repair the HPA axis responsiveness.
CRH may not be necessary in corticosterone se-
cretion in inflammation.9 CRH KO mice have a cellular
inflammatory response 50% greater than that of WT
mice after administrating carrageenin subcutaneously.
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However, their level of inflammatory response is similar
after adrenalectomy plus glucocorticoid supplement.
Hence, the effect of CRH deficiency on immune func-
tion is mainly due to the reduction of glucocorticoid
secretion. Furthermore, adrenalectomy leads to a 7-
fold fall in the inflammatory response of CRH KO mice
whereas it has no effect in WT mice. The results dem-
onstrate that the presence of pro-inflammatory factor
within the adrenal gland has not been eliminated. The
injection of CRH receptor antagonist, antalarmin, could
reduce the acute inflammatory response. But after
adrenalectomy, the inflammatory response is the same
to these two types of mice. Thus, the genetic and phar-
macological CRH deficiency could reduce inflamma-
tory responses in combination with adrenalectomy.
Finally, the stimulation of acute response is confirmed
to be included in the actions of epinephrine.
Peripheral CRH as an immunoreactive neuropep-
tide
The peripheral CRH, immunoreactive CRH, is in-
volved in regulating immune inflammatory responses
as an autocrine or paracrine inflammatory cytokine. The
contribution of peripheral CRH has synergistic pro-in-
flammatory effect with epinephrine in acute inflamma-
tory responses.10 The administration of rabbit antise-
rum to CRH causes the suppression of both inflamma-
tory exudate volume and cell concentration. The CRH
receptor antagonist can reduce the carrageenin-induced
inflammation and adjuvant-mediated arthritis. In the early
phase of inflammation, the antiserum to CRH is shown
to alleviate the uveitic symptom in mice.11 The adminis-
tration of CRH causes the peripheral vasodilatation,
congestion and hypotension due to the fluid accumula-
tion of third space in primate and human. Similarly,
intravenous injection of CRH can promote the leuko-
cyte margination, adherence and chemotaxis, and
stimulate the immune responses. The subcutaneous
administration of CRH can induce the increase in the
capillary permeability and degranulation in mast cells
in a dose-dependent manner. The effect seems more
evident as compared with secretogogue of mast cells.
The degranulation in mast cells of stress rats’ brain is
completely suppressed after the pretreatment of the
antiserum to CRH, indicating the essential pro-inflam-
matory role in peripheral CRH in mast cells.
In the course of initiation, transmission and regula-
tion of inflammatory responses, high concentration of
CRH is shown to stimulate the secretion of IL-1 in
monocytes, IL-2 in lymphocytes and IL-6 and
chemokines in mononuclear cells, and the expression
of IL-2 receptor and oxygen-derived free radicals in
macrophages. It is also involved in the opiate-like sub-
stance-induced analgesia. In the psychological and
physiological stress, the local CRH in skin or periph-
eral nerves could mediate the interactions between
HPA-like system and central HPA axis.12 According to
the previous researches, the CRH in peripheral nerves
constitute the axon reflex loop with immune cells. The
pro-inflammatory mediators from peripheral immune
cells further result in the recruitment immune cells in
inflammation locus and activate the local immune helper
cells in the regulation of inflammation.
Researches in vivo and in vitro demonstrated that
CRH could enhance the responsiveness to LPS stimu-
lat ion in either RAW 264.7 macrophages or
thioglycolate-induced peritoneal macrophages. The
amount of cytokines, TNF-α, IL-1β and IL-6
increased. CRH receptor antagonist, antalarmin, could
inhibit these courses, and prolong the survival time in
endotoxemia mice, especially in the early phase of
endotoxic shock. Hence, CRH might directly regulate
the immune functions at the macrophage levels.13 The
acute inflammatory responses induced by carrageenin
are more serious in CRH KO mice compared to WT
mice, partly due to the reduction of glucocorticoid. But
the persistent exposure to glucocorticoid is shown to
alleviate the inflammation in CRH KO mice compared
to WT mice. Thus, the pro-inflammatory effect of pe-
ripheral CRH is abolished after CRH knockout. In
addition, the proliferation of splenocytes is suppressed
in CRH deficiency. The reduction of TNF-α and IL-1β
after LPS stimulation is probably due to the lower DNA
binding capacity of NF-κB.
Concerning the peripheral CRH in inflammation, the
anti-inflammatory effect is also viewed. The reason is
that the up-regulation of CRH in inflammatory locus is
found to relate to peripheral analgesic effect of opium.
CRH could also reduce the 5-HT-induced edema, inhibit
the carrageenin-induced inflammation in rats, and reduce
the excretion of CD11b+ cells and local hyperalgesia.
The paradoxical effect of CRH is postulated to be re-
lated to the specific state of leukocytes. Slominski et
al found that CRH could stimulate the secretion of IL-1
in resting monocytes while plays inhibitory effects after
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its activation. The inflammatory locus has plenty of
immunoreactive CRH, mainly distributed in immune
helper cells and inflammatory exudates. The neutraliz-
ing antibody of CRH exerts inhibitory effect, similar to
that of TNF-α, in immune inflammatory responses.
CRH related immune inflammatory diseases
The excessive responses of HPA axis in inflamma-
tory responses may simulate severe stress. In such
condition, the body sensitivity to infections increases
with the enhanced resistance to inflammatory disease.
Otherwise, the blunted responses in HPA axis may imi-
tate the deficiency of glucocorticoid which results in
the resistance to infections and enhanced susceptibil-
ity to inflammatory diseases. The CRH neurons in hy-
pothalamus of Lewis rats show low responsiveness to
neurotransmitters. The whole body responses to stress
of inflammatory diseases are decreased, due to the
low level of CRH secretion in hypothalamus. Likewise,
patients with active rheumatoid arthritis have low or nor-
mal levels of serum ACTH and cortisol although the
serum IL-1β and IL-6 are elevated. These patients have
showed low reactiv ity to the stress of surgical
intervention. The concentration of immunoreactive CRH
increases in the inflammatory joints of these patients.
In addition, the excessive immune-mediated inflamma-
tory responses also result from the glucocorticoid re-
sistance in target tissues. In traumatic brain injury (TBI),
the gene expression of CRH is increased quickly in
PVN and amygdala. The intracerebroventricular admin-
istration of CRH antagonist, D-Phe CRH(12-41), signifi-
cantly alleviates the injury of the rats’ cortex,14 which
indicates that CRH is directly involved in the pathogen-
esis of TBI.
In severe sepsis, the levels of serum cortisol in death
cases are significantly lower than those alive after single
intravenous injection of 100 mg CRH.15 Such low reac-
tivity to CRH stimulation might indicate dysfunction of
the endocrine organs. P substance, the inhibitors of
CRH secretion in hypothalamus, is elevated possibly
on account of the inhibition of CRH neurons in
inflammation. Otherwise, the increase in inflammatory
cytokines and interferon (IFN) -γ may restrict the HPA
axis through blocking the effect of CRH and ACTH, seen
in sepsis patients. The adrenal responses to the stress-
induced or exogenous CRH and ACTH are damaged.
The central reduction of CRH and increase in pe-
ripheral immunoreactive CRH is related to the enhance-
ment of sensitivity to autoimmune disease. The sensi-
tivity and extent to acute inflammatory responses in
female, including the expression of immunoreactive
CRH, is reduced more significantly than those in male.
The estrogen could stimulate the CRH expression. CRH
knockout mice are showed to have resistance to ex-
perimental autoimmune encephalomyelitis (EAE). The
clinical scoring and inflammatory infiltration in central
nervous system in CRH KO mice are alleviated com-
pared to WT mice.16 Furthermore, Antigen-specific re-
sponses of primed T cells as well as anti-CD3/anti-CD28
TCR costimulation decrease in CRH KO mice with de-
creased production of Th1 cytokines and increased
secretion of Th2 cytokines. WT mice treated in vivo
with a CRH antagonist have showed a decrease in IFN-
γ production by primed T cells in vitro. This effect of
CRH is independent of its ability to increase in corti-
costerone production because adrenalectomized wild-
type mice have similar disease course and severity as
control mice. Also, the I-κB phosphorylation induced
by TCR cross-linking is decreased in CRH deficiency T
cells.16 These data demonstrate that peripheral immu-
noreactive CRH plays pro-inflammatory responses
through selectively enhancing the Th1 response. Our
laboratory recently found that the CRH KO mice pos-
sessed i nhibi ted chem otax is in  peri toneal
macrophages, and enhanced bacterial translocation as
compared to WT mice after thermal injury. These re-
sults provide strong evidence for the bilateral regulatory
actions of CRH in immune inflammatory process.
Prospects
The biosystem, sophisticated open system in inte-
rior structure, keeps their homeostasis in multilateral
circumstance via the interactions of neuroendocrine and
immune systems. CRH acts as a checkpoint in these
courses. The necessity of further investigation of CRH
in the basic research of trauma and injury is
overwhelming. Recent evidence has shown that the regu-
latory pathway of CRH on immune inflammatory re-
sponses at least consists of the stimulus of the releas-
ing of ACTH and glucocorticoid with CRH alone or con-
comitance with AVP, and the receptors on the surface
of immune cells. Hence, different levels (animals,
tissues, cells molecules and genes) of interference of
CRH regulation might be considered with traditional and
advanced techniques. In the research of posttraumatic
stress around the CRH mediated neuroendocrine
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pathway, the functional inactivation of CRH in the spe-
cific brain areas will help to disclose the compensatory
or concomitant effects in the lack of CRH and adrenal
hormones. Furthermore, the strategy of exogenous
supplement and endogenous excitation is reasonable
for the consonance of neuroendocrine regulated immune
inflammatory responses, which might be of great im-
portance for the abundance of trauma theory and im-
provement of its remedy.
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